Kintara Therapeutics Performance
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
The company secures a Beta (Market Risk) of 0.18, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kintara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kintara Therapeutics is expected to be smaller as well. Kintara Therapeutics right now secures a risk of 7.76%. Please verify Kintara Therapeutics potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Kintara Therapeutics will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kintara Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Kintara Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 1.5 M |
Kintara |
Kintara Therapeutics Relative Risk vs. Return Landscape
If you would invest 669.00 in Kintara Therapeutics on September 17, 2024 and sell it today you would lose (39.00) from holding Kintara Therapeutics or give up 5.83% of portfolio value over 90 days. Kintara Therapeutics is currently generating 0.0448% in daily expected returns and assumes 7.759% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Kintara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kintara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kintara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kintara Therapeutics, and traders can use it to determine the average amount a Kintara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KTRA |
Estimated Market Risk
| 7.76 actual daily | 69 69% of assets are less volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kintara Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kintara Therapeutics by adding Kintara Therapeutics to a well-diversified portfolio.
Kintara Therapeutics Fundamentals Growth
Kintara Stock prices reflect investors' perceptions of the future prospects and financial health of Kintara Therapeutics, and Kintara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kintara Stock performance.
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 17.98 M | |||
| Shares Outstanding | 55.66 M | |||
| Price To Book | 7.81 X | |||
| EBITDA | (8.5 M) | |||
| Cash And Equivalents | 11.78 M | |||
| Cash Per Share | 0.15 X | |||
| Total Debt | 2.44 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (7.18 M) | |||
| Earnings Per Share | (11.20) X | |||
| Total Asset | 6.2 M | |||
| Retained Earnings | (159.88 M) | |||
About Kintara Therapeutics Performance
By analyzing Kintara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Kintara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kintara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kintara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Kintara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.Things to note about Kintara Therapeutics performance evaluation
Checking the ongoing alerts about Kintara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kintara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kintara Therapeutics is now traded under the symbol HURA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Kintara Therapeutics is not yet fully synchronised with the market data | |
| Kintara Therapeutics had very high historical volatility over the last 90 days | |
| Kintara Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kintara Therapeutics currently holds about 11.78 M in cash with (7.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. |
- Analyzing Kintara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kintara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Kintara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kintara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kintara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kintara Therapeutics' stock. These opinions can provide insight into Kintara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |